MEDIFIRST SOLUTIONS ANNOUNCES UPDATE REGARDING SALES
AND OPERATIONS
October 17 2016 - 12:45PM
InvestorsHub NewsWire
Freehold, NJ – October 17, 2016 – InvestorsHub NewsWire
-- MEDIFIRST SOLUTIONS, INC. (OTCQB: MFST) (the
“Company” or “Medifirst”) would like to update shareholders
regarding recent company developments regarding its FDA cleared
Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic
Device.
Medifirst is pleased to announce that it anticipates completing its
FDA mandated internal controls and compliance procedures within the
next 30 days. Additionally, the Company has completed setting up
its sales and training operation in its new location in Marlboro,
New Jersey and has begun to hire a sales force to initiate sales
and set up events to introduce the Time Machine Laser to healthcare
professionals. Commented President Bruce J. Schoengood, “We are
excited to be initiating sales, which we expect to begin Q1 2017
and the company is now fast-tracked to completing all internal
compliance, setting up sales infrastructure and purchasing
additional inventory and accessories to initiate sales.” Fifty
additional laser units, with an anticipated wholesale value of
approximately $500,000, have been ordered for the initial sales
roll-out. In addition, custom cases have been designed and
ordered. Regarding international sales, Medifirst is pleased to
announce that it currently has a Sales Director setting up sales
operations and territories including compliance in Dubai, various
Mid-East countries, Morocco, Spain and Africa. Commented CEO
Schoengood, “The initial reaction to our Laser in the International
Market has been extremely positive and we are committed to
providing the resources and personnel necessary to build an
international brand. Our price point and manufacturing cost will
allow us to be very competitive in the global marketplace.” The
Company appreciates the patience of its shareholders and supporters
during this exciting time and will continue to provide updates in
the upcoming days and weeks.
About Medifirst Solutions, Inc.
Medifirst Solutions, Inc., in response to its Premarket
Notification 510(k) submission for “The Time Machine” Series Laser,
received clearance from the U.S. Food and Drug Administration
(“FDA”) to market its infrared Time Machine TTML-8102000 Laser
Thermal Therapeutic Device. The Time Machine Series Lasers Model
TTML-8102000 - 810/830nm is intended for use in temporary relief of
minor muscle and joint pain, stiffness, minor arthritis pain,
muscle spasm, temporary increase in local blood circulation and
temporary relaxation of muscles by means of topical elevated tissue
temperature from infrared spectral emissions. Due to the
decrease of inflammation, patients have seen immediate aesthetic
improvements as well, such as in scar and incision healing. The
hand-held laser device, with pin-point accuracy, often gives
patients immediate results with no redness, swelling or down-time.
This unique laser device offers medical professionals an affordable
and effective tool to enhance their treatment protocols for their
patients and provide new revenue streams for their practice. The
laser division will be operated out of Medifirst's wholly owned
subsidiary, Medical Lasers Manufacturer. Visit
www.medifirstsolutions.com for more information.
Forward-Looking Statements:
The statements in this press release that relate to the company's
expectations with regard to the future impact on the company's
results from new products in development are forward-looking
statements, and may involve risks and uncertainties, some of which
are beyond our control. Such risks and uncertainties are
described in greater detail in our filings with the U.S. Securities
and Exchange Commission. Since the information in this press
release may contain statements that involve risk and uncertainties
and are subject to change at any time, the company's actual results
may differ materially from expected results. We make no
commitment to disclose any subsequent revisions to forward-looking
statements. This release does not constitute an offer to sell or a
solicitation of offers to buy any securities of any entity.
Contact: Investor Relations
Phone: (732) 786-8044
Email:
admin@medifirstsolutions.com
Website: www.medifirstsolutions.com